Ertumaxomab is an intact bispecific antibody targeting HER2/neu and CD3, with preferential binding to activating Fc gamma type I/III-receptors, under investigation for metastatic breast cancer treatment after trastuzumab progression. The DrugMonitor™ Anti-Ertumaxomab Antibody (VS-1224-YC447) is an anti-drug antibody (ADA) against Ertumaxomab. This drug-based antibody is raised in mice immunized with the Ertumaxomab. The anti-Ertumaxomab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Ertumaxomab in samples.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Anti-Human CD3E Recombinant Antibody (Ertumaxomab)Recombinant Rat antibody to Human CD3E. Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer. It is a so-called trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells.
There are currently no Customer reviews or questions for VS-1224-YC447. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.